Lennox-Gastaut syndrome
MONDO:0016532Lennox-Gastaut syndrome (LGS) belongs to the group of severe childhood epileptic encephalopathies.
Also known as: LGS, encephalopathy of childhood, epileptic encephalopathy Lennox-Gastaut type, macrocephaly and epileptic encephalopathy
40 clinical trials for this condition and its sub-types, 26 tagged with Lennox-Gastaut syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Lennox-Gastaut syndrome
-
New hope for Hard-to-Treat seizures: phase 3 trial launches
Disease control OngoingThis study tests an experimental drug called LP352 to see if it can safely reduce seizures in children and adults with developmental and epileptic encephalopathies (DEE), a group of severe epilepsy syndromes. About 320 participants will receive either LP352 or a placebo, and rese…
Phase 3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Brain implant shows promise for Hard-to-Treat seizures in rare epilepsy
Disease control OngoingThis study tests a brain-responsive neurostimulation system in 24 people aged 12 and older with Lennox-Gastaut syndrome whose seizures are not controlled by medication. The device detects and responds to seizure activity in the brain to reduce drop seizures. The goal is to see if…
Phase 2 • Sponsor: NeuroPace • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug LP352 aims to control seizures in severe epilepsy over the long term
Disease control By invitation onlyThis phase 3 study is testing the long-term safety and effectiveness of LP352 (Bexicaserin) in 324 children and adults with developmental and epileptic encephalopathy (DEE), including Dravet and Lennox-Gastaut syndromes. Participants who completed earlier studies will receive LP3…
Phase 3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
CBD epilepsy drug under Real-World watch for rare seizure disorders
Disease control OngoingThis study follows about 111 people with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex who are taking Epidyolex (a CBD oral solution) for seizures. Researchers track how many stay on the drug for a year and how many seizure-free days they have. It's an o…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Brain pacemaker shows promise for rare childhood epilepsy
Disease control OngoingThis pilot study tests whether deep brain stimulation (DBS) of specific brain pathways can safely reduce seizures in people with Lennox-Gastaut syndrome, a severe form of epilepsy. Five participants receive the electrical stimulation as an add-on to their usual treatment. The goa…
Sponsor: Liankun_Ren • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Bridge program keeps seizure drug available for eligible patients
Disease control Expanded access (ended)This program provides continued access to the seizure medication perampanel (Fycompa) for people who completed certain earlier studies and are still benefiting from the drug. It runs until the drug is commercially available in their country or no participants remain. Only those a…
Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:19 UTC
-
Epidiolex liver check: is Long-Term use safe?
Knowledge-focused OngoingThis study follows 154 people taking Epidiolex (cannabidiol) for seizures caused by Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Researchers will monitor for signs of chronic liver injury and fibrosis over time using blood tests and liver scans. The go…
Phase 4 • Sponsor: Jazz Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Counting the uncounted: a nationwide look at two rare epilepsies
Knowledge-focused CancelledThis observational study aims to measure how many people in Portugal have Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS), two rare and severe forms of epilepsy. Researchers will review existing medical records from about three public hospitals to estimate the percentage of…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
EEG clues may reveal who benefits from seizure drug
Knowledge-focused By invitation onlyThis study looks at whether specific brain wave patterns on an EEG can predict how well the drug fenfluramine works for people with Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy. Researchers will follow 20 children and adults aged 2 to 35 who are already taking fenflur…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC